At Aprea, we are committed to the discovery and development of novel, targeted anti-cancer compounds. The goal of our development program is to expeditiously bring our investigational therapies to markets, so as to potentially provide benefit for the greatest number of patients. We believe that focusing on our clinical trials is the most appropriate way to achieve this goal. Therefore, at this time, we do not offer access to our investigational product candidates outside of our clinical trials and we do not have any Expanded Access or Compassionate Use programs.
We are conducting clinical trials to obtain clinical data required for submission, review and approval by regulatory authorities of marketing applications for our investigational therapies. In this regard, we welcome patients seeking to participate in our trials. To obtain further information regarding our clinical trials and potential opportunities to participate, please see details posted on ClinicalTrials.gov.
For all inquiries relating to our clinical trials, please contact: email@example.com
Consistent with the 21st Century Cures Act, Aprea may revise this Expanded Access policy at any time. This policy applies to all of Aprea’s investigational products.